BCLSI
PNT

Bain Capital Life Sciences Investors’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio PNT Stock Details PNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,000,000
Closed -$10.5M – 31
2021
Q1 		$10.5M Hold
1,000,000
– – 0.6% 23
2020
Q4 		$13.9M Hold
1,000,000
– – 0.87% 18
2020
Q3 		$14.4M Buy
+1,000,000
New +$13.6M 1.34% 17

Other funds holding PNT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Bain Capital Life Sciences Investors's PNT Position: Q2 2021 in Review

Bain Capital Life Sciences Investors sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q2 2021, closing a stake of 1,000,000 shares — an estimated $10.5M sold.

Bain Capital Life Sciences Investors first reported a position in PNT in Q3 2020 and held it in 3 quarters. The position peaked at $14.4M in Q3 2020. 21 funds tracked by Wall St. Rank hold PNT as of Q2 2021.

  • Bain Capital Life Sciences Investors reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Bain Capital Life Sciences Investors sold 1,000,000 POINT Biopharma Global Inc. Common Stock shares in Q2 2021, an estimated $10.5M.
  • Bain Capital Life Sciences Investors first reported a position in POINT Biopharma Global Inc. Common Stock in Q3 2020 and held it in 3 quarters.
  • Bain Capital Life Sciences Investors's POINT Biopharma Global Inc. Common Stock position peaked at $14.4M in Q3 2020.
  • 21 funds tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q2 2021.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2021, filed 16 Aug 2021.